» Articles » PMID: 24030498

Oxidized Ca(2+)/calmodulin-dependent Protein Kinase II Triggers Atrial Fibrillation

Abstract

Background: Atrial fibrillation (AF) is a growing public health problem without adequate therapies. Angiotensin II and reactive oxygen species are validated risk factors for AF in patients, but the molecular pathways connecting reactive oxygen species and AF are unknown. The Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) has recently emerged as a reactive oxygen species-activated proarrhythmic signal, so we hypothesized that oxidized CaMKIIδ could contribute to AF.

Methods And Results: We found that oxidized CaMKII was increased in atria from AF patients compared with patients in sinus rhythm and from mice infused with angiotensin II compared with mice infused with saline. Angiotensin II-treated mice had increased susceptibility to AF compared with saline-treated wild-type mice, establishing angiotensin II as a risk factor for AF in mice. Knock-in mice lacking critical oxidation sites in CaMKIIδ (MM-VV) and mice with myocardium-restricted transgenic overexpression of methionine sulfoxide reductase A, an enzyme that reduces oxidized CaMKII, were resistant to AF induction after angiotensin II infusion.

Conclusions: Our studies suggest that CaMKII is a molecular signal that couples increased reactive oxygen species with AF and that therapeutic strategies to decrease oxidized CaMKII may prevent or reduce AF.

Citing Articles

Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases.

Roselli C, Surakka I, S Olesen M, Sveinbjornsson G, Marston N, Choi S Nat Genet. 2025; 57(3):539-547.

PMID: 40050429 DOI: 10.1038/s41588-024-02072-3.


Relationship between elevated serum direct bilirubin and atrial fibrillation risk among patients with coronary artery disease.

Song Y, Li W Front Med (Lausanne). 2025; 12:1405682.

PMID: 40027894 PMC: 11868094. DOI: 10.3389/fmed.2025.1405682.


SGLT2 inhibitors protect against diabetic cardiomyopathy and atrial fibrillation through a CaMKII independent mechanism.

Severino A, Reyes-Gaido O, Nguyen P, Elkarim A, Luczak E, Mesubi O bioRxiv. 2024; .

PMID: 39386626 PMC: 11463538. DOI: 10.1101/2024.09.23.614368.


Common Genetic Variant Associated With Atrial Fibrillation Lowers Expression of Nesprin-2α1 With Downstream Effects on Nuclear and Electrophysiological Traits.

Liu N, Hsu J, Mahajan G, Sun H, Laurita K, Naga Prasad S Circ Genom Precis Med. 2024; 17(5):e004750.

PMID: 39355904 PMC: 11522946. DOI: 10.1161/CIRCGEN.124.004750.


Gene therapy for atrial fibrillation.

Mo W, Donahue J J Mol Cell Cardiol. 2024; 196:84-93.

PMID: 39270930 PMC: 11534567. DOI: 10.1016/j.yjmcc.2024.09.004.


References
1.
Negi S, Shukrullah I, Veledar E, Bloom H, Jones D, Dudley S . Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol. 2010; 22(4):414-9. PMC: 3022954. DOI: 10.1111/j.1540-8167.2010.01925.x. View

2.
Zhang R, Khoo M, Wu Y, Yang Y, Grueter C, Ni G . Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11(4):409-17. DOI: 10.1038/nm1215. View

3.
Koval O, Guan X, Wu Y, Joiner M, Gao Z, Chen B . CaV1.2 beta-subunit coordinates CaMKII-triggered cardiomyocyte death and afterdepolarizations. Proc Natl Acad Sci U S A. 2010; 107(11):4996-5000. PMC: 2841943. DOI: 10.1073/pnas.0913760107. View

4.
Benjamin E, Wolf P, DAgostino R, Silbershatz H, Kannel W, Levy D . Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98(10):946-52. DOI: 10.1161/01.cir.98.10.946. View

5.
Lee J, Kalman J . Sinus node dysfunction and atrial fibrillation: two sides of the same coin?. Europace. 2012; 15(2):161-2. DOI: 10.1093/europace/eus223. View